Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

20091,185 citationsJournal Articlebronze Open Access

Authors

John G. McHutchison · Duke Medical Center

Eric Lawitz · Seno Medical (United States)

Mitchell L. Shiffman · Virginia Commonwealth University

Andrew J. Muir · Clinical Research Institute

Greg Galler · Kelsey Research Foundation

Jonathan McCone

Lisa M. Nyberg · Kaiser Permanente San Diego Medical Center

Abstract

In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between the two available peginterferon-ribavirin regimens or between the two doses of peginterferon alfa-2b. (ClinicalTrials.gov number, NCT00081770.)

Topics & Keywords

Hepatitis C virus research Liver Disease Diagnosis and Treatment Hepatitis B Virus Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 361, Issue 6, pp. 580-593

DOI: 10.1056/nejmoa0808010

Field-Weighted Citation Impact: 80.29